Canaccord lowered the firm’s price target on Zevra Therapeutics (ZVRA) to $24 from $25 and keeps a Buy rating on the shares. The firm lowered its target on a softening Europe Miplyffa ramp.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA: